Enliven Therapeutics, Inc.
ELVN
$27.25
-$0.54-1.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -29.67M | -20.15M | -25.34M | -28.54M | -23.18M |
| Total Depreciation and Amortization | 46.00K | 62.00K | 81.00K | 74.00K | 80.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.56M | 6.96M | 7.88M | 6.84M | 6.41M |
| Change in Net Operating Assets | 1.22M | -157.00K | 313.00K | -2.50M | -510.00K |
| Cash from Operations | -15.84M | -13.28M | -17.06M | -24.13M | -17.20M |
| Capital Expenditure | 0.00 | 1.00K | -139.00K | -20.00K | 0.00 |
| Sale of Property, Plant, and Equipment | 213.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.17M | -4.06M | -183.45M | 1.45M | 727.00K |
| Cash from Investing | 12.38M | -4.06M | -183.59M | 1.43M | 727.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 721.00K | -- | 218.38M | 234.00K | 39.97M |
| Repurchase of Common Stock | -- | -249.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -98.00K | -119.00K | -- | -- | -- |
| Cash from Financing | 623.00K | -368.00K | 218.38M | 234.00K | 39.97M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.84M | -17.71M | 17.73M | -22.47M | 23.50M |